Teva Pharmaceutical Industries (TEVA) announced positive results from a Phase III trial around mid-morning Wednesday. The trial was evaluating the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane Nasal Aerosol in the treatment of seasonal allergic rhinitis. The study met all efficacy endpoints, demonstrating a statistically significant benefit, compared to placebo.
Teva Pharmaceutical steadily declined during the first hour of trade Wednesday, before settling into a range. Shares finished down by 1.67 at $48.44 on above average volume. Teva dropped to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.